The molecular dynamics of a solid drug strongly affects its pharmaceutical properties and other important characteristics as solid state degradation. Understanding the mobility of molecular moieties in solid drugs can also lead to a deeper knowledge of the factors responsible for conformational interconversions and solid state reactions [1]. Moreover, dynamics plays an important role in drug-excipient interactions, which significantly affect the release properties. Many active pharmaceutical ingredients (APIs) show a limited and variable bioavailability mainly associated to inadequate biopharmaceutical properties such as aqueous solubility and dissolution rate. The latter is the main factor responsible for the limited efficacy of many biopharmaceutics classification system (BCS) class II and class IV orally administered drugs. In this context, the employment of inorganic matrices, such as mesoporous materials and lamellar anionic clays, for the preparation of host-guest composites is a suitable strategy for improving biopharmaceutical properties [2]. Indeed, some inorganic matrices are able to host drugs into nanometric galleries or pores in a non-crystalline form. In this way rapid dissolution can occur after the contact with the dissolution medium, without the need of a previous modification of the API chemical structure. The characterization of the solid form, chemical environment and dynamic properties of the API in this kind of formulations therefore appears particularly relevant. In this work, the dynamic properties of ibuprofen, a widely used non-steroidal analgesic and anti-inflammatory drug belonging to BCS class II, have been investigated in detail both in pure crystalline forms of the API and in an innovative formulation where ibuprofen is intercalated in a Hydrotalcite (HTlc) clay. In the presented work, the potentialities offered by solid state NMR to study molecular dynamics have been extensively exploited, and a combined analysis of a wide set of experiments provided qualitative and quantitative information about the motions of the various molecular fragments (phenyl ring, methyl groups, aliphatic chains) [4, 5]. The comparison of spectral and relaxation properties of ibuprofen in its pure form and in formulation with HTlc allowed interesting differences to be highlighted and discussed. In particular, all the NMR experiments revealed a much higher mobility of ibuprofen when it is intercalated in HTlc with respect to the pure compound and a motion involving the whole ibuprofen molecule could be identified and characterized [6]. [1] S. R. Byrn , W. Xu , A. W. Newman, Adv. Drug Deliver. Rev. 2001, 48, 115 - 136. [2] L. Perioli, C. Pagano. Expert Opin. Drug Deliv. 2012, 9, 1559-1572. [3] E. Conterosito et al. Cryst. Growth Des. 2013, 13, 1162-1169. [4] E. Carignani, S. Borsacchi, M. Geppi, ChemPhysChem, 2011, 12, 974-981. [5] E. Carignani, S. Borsacchi, M. Geppi, J. Phys. Chem. A, 2011, 115, 8783-8790. [6] E. Carignani, S. Borsacchi, P. Blasi, A. Schoubben, M. Geppi, Mol. Pharm. Article ASAP, DOI: 10.1021/acs.molpharmaceut.9b00160.
Dynamic properties of pharmaceuticals by solid state NMR spectroscopy: from pure active ingredients to formulations
E Carignani;S Borsacchi;L Calucci;M Geppi
2019
Abstract
The molecular dynamics of a solid drug strongly affects its pharmaceutical properties and other important characteristics as solid state degradation. Understanding the mobility of molecular moieties in solid drugs can also lead to a deeper knowledge of the factors responsible for conformational interconversions and solid state reactions [1]. Moreover, dynamics plays an important role in drug-excipient interactions, which significantly affect the release properties. Many active pharmaceutical ingredients (APIs) show a limited and variable bioavailability mainly associated to inadequate biopharmaceutical properties such as aqueous solubility and dissolution rate. The latter is the main factor responsible for the limited efficacy of many biopharmaceutics classification system (BCS) class II and class IV orally administered drugs. In this context, the employment of inorganic matrices, such as mesoporous materials and lamellar anionic clays, for the preparation of host-guest composites is a suitable strategy for improving biopharmaceutical properties [2]. Indeed, some inorganic matrices are able to host drugs into nanometric galleries or pores in a non-crystalline form. In this way rapid dissolution can occur after the contact with the dissolution medium, without the need of a previous modification of the API chemical structure. The characterization of the solid form, chemical environment and dynamic properties of the API in this kind of formulations therefore appears particularly relevant. In this work, the dynamic properties of ibuprofen, a widely used non-steroidal analgesic and anti-inflammatory drug belonging to BCS class II, have been investigated in detail both in pure crystalline forms of the API and in an innovative formulation where ibuprofen is intercalated in a Hydrotalcite (HTlc) clay. In the presented work, the potentialities offered by solid state NMR to study molecular dynamics have been extensively exploited, and a combined analysis of a wide set of experiments provided qualitative and quantitative information about the motions of the various molecular fragments (phenyl ring, methyl groups, aliphatic chains) [4, 5]. The comparison of spectral and relaxation properties of ibuprofen in its pure form and in formulation with HTlc allowed interesting differences to be highlighted and discussed. In particular, all the NMR experiments revealed a much higher mobility of ibuprofen when it is intercalated in HTlc with respect to the pure compound and a motion involving the whole ibuprofen molecule could be identified and characterized [6]. [1] S. R. Byrn , W. Xu , A. W. Newman, Adv. Drug Deliver. Rev. 2001, 48, 115 - 136. [2] L. Perioli, C. Pagano. Expert Opin. Drug Deliv. 2012, 9, 1559-1572. [3] E. Conterosito et al. Cryst. Growth Des. 2013, 13, 1162-1169. [4] E. Carignani, S. Borsacchi, M. Geppi, ChemPhysChem, 2011, 12, 974-981. [5] E. Carignani, S. Borsacchi, M. Geppi, J. Phys. Chem. A, 2011, 115, 8783-8790. [6] E. Carignani, S. Borsacchi, P. Blasi, A. Schoubben, M. Geppi, Mol. Pharm. Article ASAP, DOI: 10.1021/acs.molpharmaceut.9b00160.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.